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Abstract: Critical to survival is the geriatric concept, allostasis, deﬁ  ned as the ability to achieve 
stability through change. It is appropriate that allostasis is an introduction to this commentary, 
which may partially apply to the medical and pharmacy profession as currently constituted.
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Before writing a prescription, physicians must consider a number of factors including 
the pharmacodynamics and pharmacokinetics of the drug and how these might be 
affected by aging, polymedicine, adverse drug effects, and the potential for drug–drug 
interactions and patient nonadherence. As our knowledge of genetic polymorphisms 
associated with altered metabolism, drug distribution, and receptor afﬁ  nity increase, 
it is likely that drugs which could not receive regulatory approvals in the past might 
now be approved for certain subsets of patients. Further complicating matters is the 
impact of direct consumer advertising, which increases consumer demand for products 
and services and may alter prescribing practices. This commentary will address these 
issues and make some suggestions for a partial solution.
With the increasing elderly population in the US, there are too few geriatricians. 
This has the result that most geriatric care is provided by primary care physicians 
who may not be familiar with or fully take into account the dynamics of aging on 
drug prescribing. In geriatric practice, as in any medical practice, the physician 
must consider the patient’s gender, age, life style, (tobacco, alcohol, street drugs, or 
eating habits resulting in obesity); comorbities, personality (adherence), any other 
prescription drugs, and over-the-counter drugs, including herbal medications taken 
by the patient (drug–drug interactions). In the geriatric population, however, the 
writing of a prescription is a far more complex procedure than many members of the 
medical profession recognize. This complexity is largely driven by the consequences 
of aging as brieﬂ  y presented below. Several excellent reviews cover these topics in 
much greater detail (Bressler and Bahl 2003; Caﬁ  ero 2004; Goodman et al 2005; 
Petron and Katz 2005).
Pharmacokinetics involves absorption, distribution, metabolism, and excretion 
of drugs. Pharmacodynamics relate to a drug mechanism of action and its effect at 
the targeted receptor site, ie, what the drug does to the body. Depending on the drug, 
the aging process may have a signiﬁ  cant effect on a drug’s kinetics or dynamics 
(McLean and Le Couteur 2004). The physiology of aging with decreased body 
size and lean body mass requires decreased dosages. Increased body fat results in 
increased distribution of fat-soluble drugs. Decreased body water results in decreased 
distribution of water soluble drugs and ﬁ  nally decreased serum albumin produces 
an increased free fraction of drug in serum. These changes due to aging raise the 
potential for adverse effects. All of these factors signiﬁ  cantly impact on the dosing of 
many drugs. Recognizing this impact has practical implications. First, initiating drug 
therapy at lower doses is usually appropriate for elderly patients. Second, patients Clinical Interventions in Aging 2007:2(4) 716
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Creatinine clearance
=
 (140–age) × lean body weight (kg)
Plasma creatinine (mg/dl) × 72
      multipled by 0.85 for females  (1)
Therefore, decreased doses in the elderly would be prudent, 
especially for those drugs where the parent compound or an active 
metabolite relies on renal elimination. Despite the availability 
of various methods to estimate renal function, it is not unusual 
for prescribers to look at a serum creatinine of 0.9 mg/dl in an 
elderly patient and conclude, “normal renal function”.
Patients in the geriatric group frequently have a variety 
of chronic conditions requiring multiple medications and 
often receive care from several physicians. Furthermore, 
these patients may utilize several pharmacies increasing the 
risk for duplicative therapy and adverse drug reactions. This 
fact increases the risk of adverse drug effects when added 
to the previously discussed physiologic and pharmacologic 
changes in aging. In some instances the adverse effect 
may be misinterpreted by the physician as a new medical 
condition and result in a new prescription, which could 
result in additional adverse effects. Recently, Representative 
Patrick Kennedy, of Rhode Island, the son of Senator Edward 
Kennedy, had a bizarre adverse drug reaction in Washington. 
He awoke in the middle of the night and thought he had a 
vote to cast, dressed, and got in his car, and an automobile 
accident followed. Fortunately, no one was injured. The 
initial media reaction was he was drunk. His explanation was 
that he took a hypnotic to help him sleep with an antiemetic 
for gastroenteritis. This drug–drug interaction produced 
confusion and cognitive impairment and was a satisfactory 
explanation. Drug–drug interactions are not uncommon and 
all physicians should be aware of the possibility.
The seminal Institute of Medicine report (Kohn and 
Donaldson 1999) on patient safety provided extensive 
detail on medication errors and their sequelae as well as 
preventable adverse drug events in acute care but little was 
known about similar problems in ambulatory care. A recent 
report indicated these events in ambulatory care are common; 
many are preventable and many result in hospitalization 
(Thomsen et al 2007).
Problems occurred in cardiovascular drugs, analgesic, 
and hypoglycemic drugs, which are common drug classes 
used by the elderly (Goulding 2004; Schmader et al 2004; 
Gurwitz et al 2005; Simon et al 2005).
A related problem is poly-medicine, which is an excessive 
and inappropriate use of medications. Many elderly take 
5 or more medications. Simply requiring all patients to 
may not tolerate a drug even at lower doses. Except in 
cases of true allergy, further dose reductions might improve 
tolerability and still offer a therapeutic beneﬁ  t. It should be 
remembered that to be commercially viable drugs need to 
balance effectiveness with safety and there is little incentive 
to ﬁ  nd the minimally effective dose. While this assures that 
the marketed dosage will demonstrate its therapeutic effect 
in the majority of recipients, it also results in some patients 
experiencing side effects because lower dose options are 
not available.
Alterations in organ function in the elderly can 
signiﬁ  cantly alter dosing requirements. Let us start with the 
intake of medication in the gastrointestinal (GI) tract. In 
aging, there is decreased salivation, decreased gastric acidity, 
and decreased gastric emptying time. The upper GI tract 
usually has a clinically insigniﬁ  cant impact on drug therapy, 
except that diminished salivation and esophageal motility 
disorders may cause difﬁ  culty with swallowing drugs. Even 
this issue can be problematic as evidenced by the precautions 
related to bisphosphonate use in these patients.
In aging, there are alterations in phase I and II path-
ways of hepatic drug metabolism (Cotreau et al 2005). 
Phase lI pathways convert drugs to metabolites which 
decrease, increase, or have no change in the action of the 
original drug. Phase I pathways convert drugs to inactive 
metabolites, which do not accumulate. With few exceptions; 
drugs metabolized by phase I pathways are preferred for older 
patients. Listing the drugs dealt with by phase l or ll is beyond 
the scope of this paper. Cytochrome P450 enzymes, with the 
highest concentrations in the liver and small intestine, are a 
primary method of drug metabolism.
The role of these enzymes in hepatic drug metabolism 
is complex, but it is generally a good rule to decrease 
doses of hepatically metabolized drugs in elderly patients. 
The patient’s concomitant therapy may interact with these 
enzymes to increase or decrease the effect of the drug the 
physician wants to add to the regimen. Even foods such as 
grapefruit juice can interact with these enzymes and result in 
dangerous, and at times life threatening, arrhythmias when 
combined with drugs such as erythromycin in a predisposed 
patient (Wilkinson 2005; Bressler 2006).
Signiﬁ  cant decreases in renal function occur as we age with 
a very important impact on drug elimination. The glomerular 
ﬁ  ltration rate must decline to about one half the normal level 
before the serum creatinine concentration rises above the upper 
limit of normal. The Cockcroft-Gault formula can estimate 
creatinine clearance based on the age of the patient and the 
weight (Cockcroft and Gault 1976).
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bring all medications including over-the-counter drugs and 
herbal medications to each ofﬁ  ce visit for the physician to 
review can reduce the potential for adverse effects. Patients 
usually will not inform their physicians of the use of herbal 
medications. With very few exceptions, none of these herbal 
medications have any more beneﬁ  t when compared with 
available prescription drugs. Physicians must always consider 
an adverse drug reaction as a cause of a new symptom and 
avoid adding a new drug to treat the symptom rather than 
discontinuing a medication.
The other issue that the prescribing physician must 
consider is patient nonadherence to the medication. 
Obviously, a drug has no effect if it is not taken (Kulkarni 
et al 2006). The use of the term adherence indicates a 
relationship between the doctor and the patient so that the 
patient understands and is educated about the indications and 
action of the drugs. There are many reasons that patients do 
not take prescribed medications. Many drugs are expensive; 
side effects are objectionable, the patient does not understand 
how to take the drug or why the drug should be used at all.
The multiple factors described above make prescribing 
for the elderly patient difﬁ  cult enough, but two more recent 
developments have the potential to make prescribing 
drug therapy in the elderly even more challenging. While 
seemingly unrelated they are in a sense polar opposites. The 
ﬁ  rst is direct to consumer advertising of pharmaceuticals and 
the other is ethnopharmacolgy.
The United States and New Zealand are the only 
industrialized countries to allow direct-to-consumer 
advertising (Gellad and Lyles 2007). Although patients 
may benefit through increased disease awareness and 
increased adherence (Bradford et al 2006), this practice 
has the potential to increase healthcare costs, and may 
result in misunderstandings by the patients about their 
underlying disease and its management with poor use of 
clinic time (Bosic et al 2007). This is a serious problem in 
these days of managed care. Direct-to-consumer advertising 
of pharmaceuticals works best in certain circumstances. 
Of course, the advertiser must have an approved product 
that has been shown to be safe and effective. Generic 
equivalents should not exist and the condition being treated 
should be commonplace. The dosing regimen should be 
simple and it helps if certain advantages are identiﬁ  ed over 
competing therapies (even if these exist only in the eyes of 
the advertiser). Since these conditions do not exist for a drug 
like warfarin, for example, it is unlikely that an advertising 
campaign will emerge despite the large number of potential 
beneﬁ  ciaries. Since 2000 direct-to-consumer advertising of 
prescription drugs has continued to grow both in absolute 
dollars and relative to other forms of promotion. Gaining a 
better understanding of the effects of this type of promotion 
has important public health implications not only for the US 
and New Zealand where such advertising is permitted, but 
for Canada and the European Union where such advertising 
is banned but has been subject to recent challenge (Bosic 
et al 2007).
The premise of individualized drug therapy is in contrast 
to the wide appeal that drives direct-to-consumer pharmaceu-
tical advertising, ethnopharmacology, or pharmacogenomics 
(Burroughs et al 2002; Muonz and Hilgenberg 2005; Sadee 
and Dai 2005). The goal is to reﬁ  ne the drug use process to 
maximize the likelihood of response and minimize serious 
adverse reactions. As our knowledge expands in this arena it 
is likely that new drugs will be introduced to the marketplace 
that demonstrated inconsistent effectiveness or sporadic 
toxicity in the past. Their use may require the prescriber to 
genotype the patient prior to drug administration in order to 
avoid serious toxicities. Restricted access to these drugs may 
be required as is already done with products like cisapride, 
thalidomide, and clozapine.
Prescribing for the elderly has never been easy, and the 
likelihood is that it could be even more demanding. Some 
of the solutions to improving medication use already exist, 
but need to be more consistently implemented; others will 
require an overhaul of the drug distribution system.
A simple, but often underutilized approach is to have 
the patient “brown bag” all medications including “over 
the counter” medications and bring them to the ofﬁ  ce at 
every medical visit. The physician should make certain 
that the drugs prescribed are appropriate and have a known 
clinical use. Some medications that were started for an acute 
condition may no longer be needed. Others may no longer be 
providing an optimal response. Prescribers should always be 
open to discontinuing a medication or altering the regimen 
to achieve the best therapeutic outcome.
Electronic medical records with electronic transmission of 
prescriptions can screen for drug interactions and duplicative 
therapies; but are not yet widely available. Expert systems 
are being developed that facilitate safe dosing of medications 
based upon patient-speciﬁ  c parameters such as weight or 
organ function. With increasing use of these systems it will be 
important to remember that they only support the prescribing 
process and are no substitute for accurate histories and 
physical exams or clinical judgment.
To facilitate good therapeutic outcomes and reduce the 
possibility of unwanted events, physicians should collaborate Clinical Interventions in Aging 2007:2(4) 718
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with all members of the patient care team. Speciﬁ  cally 
in regard to drug therapy, pharmacists offer a potentially 
valuable resource to assess and facilitate patient adherence 
with the prescribed regimen. In the US, federal requirements 
mandate that pharmacists offer counseling for newly 
prescribed medications. Patients should be encouraged by 
the prescriber to ask the pharmacist for this service. With 
the computerization of the dispensing function, it is likely 
that the patient’s pharmacist has the most up-to-date list 
of medications and, based on reﬁ  ll records, can inform the 
physician if the patient is adherent with the drug regimen. 
Knowing the reﬁ  ll history the prescriber can more accurately 
evaluate the therapeutic response (or lack thereof  ). States 
require that pharmacists perform a prospective drug use 
review to identify potential drug interactions and other 
problems. Frequently these potential problems never 
materialize, but if they do the results could be disastrous.
In conclusion, writing a prescription is certainly not a 
simple procedure. Perhaps the best maxim to consider before 
you write a prescription is to think of what Vince Lombardi, 
the legendary coach of the Greene Bay Packers, said about 
throwing a football. He was a coach who believed in run-
ning the football and he said, “When you throw a football, 
three things could happen, and two of them are bad.” Not a 
bad concept to have when writing a prescription.
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